• ABL Diagnostics held an Extraordinary General Meeting today.
• Shareholders backed a change of corporate name to ABL Texcell Diagnostics; the vote authorizes the change, with execution not yet confirmed.
• A proposal to transfer the shares to Euronext Growth Paris was rejected; the move will not proceed based on this meeting outcome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917377394) on September 17, 2026, and is solely responsible for the information contained therein.